Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

36.10 +0.38 (+1.06%)

Delayed Quote Updated: 12:28 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

October 27, 2025

From Roivant Sciences

Via GlobeNewswire

6 Analysts Assess Roivant Sciences: What You Need To Know ↗

September 18, 2025

Via Benzinga

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17 ↗

September 17, 2025

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,...

Via Stocktwits

Why Roivant Sciences Stock Is Soaring Today ↗

September 17, 2025

The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug.

Via The Motley Fool

A Glimpse of Roivant Sciences's Earnings Potential ↗

August 08, 2025

Via Benzinga

What Does the Market Think About Roivant Sciences? ↗

July 23, 2025

Via Benzinga

Peering Into Roivant Sciences's Recent Short Interest ↗

June 25, 2025

Via Benzinga

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial ↗

September 17, 2025

Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

September 17, 2025

Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗

September 17, 2025

Via Benzinga

Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease ↗

September 17, 2025

The company is working on a treatment for an autoimmune disease that affects the skin and muscles.

Via Investor's Business Daily

Roivant Sciences's Earnings Outlook ↗

May 28, 2025

Via Benzinga

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

September 17, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

September 11, 2025

From Roivant Sciences

Via GlobeNewswire

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

September 04, 2025

From Pulmovant, Inc.

Via GlobeNewswire

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

September 03, 2025

From Roivant Sciences

Via GlobeNewswire

Why Roivant Sciences Stock Bounced Back on Tuesday ↗

August 12, 2025

Investors were in a forgiving mood after Monday's dispiriting earnings release.

Via The Motley Fool

Why Roivant Sciences Stock Was Slipping on Monday ↗

August 11, 2025

The distinctive biotech wasn't a sector favorite as the trading week began.

Via The Motley Fool

Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports

August 11, 2025

Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings....

Via MarketMinute

Topics Economy Stocks

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

August 11, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

July 28, 2025

From Roivant Sciences

Via GlobeNewswire

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025

From Pulmovant, Inc.

Via GlobeNewswire

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 09, 2025

From Roivant Sciences

Via GlobeNewswire

Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday? ↗

May 29, 2025

Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion of...

Via Benzinga

Topics Government

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 29, 2025

From Roivant Sciences

Via GlobeNewswire

Earnings Scheduled For May 29, 2025 ↗

May 29, 2025

Via Benzinga

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

May 15, 2025

From Roivant Sciences

Via GlobeNewswire

Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift ↗

April 21, 2025

The company is getting a new chief executive and a new chief financial officer amid sweeping changes.

Via Investor's Business Daily

Topics Government

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

April 21, 2025

From Roivant Sciences

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.